Listed by the USPTO as BURKHART, MICHAEL D
Tech Center 1600 • Art Units: 1633 1638 1653
This examiner grants 62% of resolved cases
BURKHART, MICHAEL D is assigned to technology center 1600 and art unit 1633. The record contains 846 resolved cases, an allowance rate of 62.4%, an interview lift of 11.8%, and a median of 1217 days to allowance. The substantial docket supports using the allowance figure for planning, while the limited interview association suggests that written claim and prior-art analysis should remain central to prosecution strategy.
The listed companies are Hoffmann-La Roche Inc., Intellia Therapeutics Inc., and Ucl Business Ltd. The listed firms are LEYDIG VOIT & MAYER, LTD, Acuity Law Group, P.C., and ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP. Counsel handling biotechnology matters should plan for the reported interval and use interviews selectively for focused technical issues.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17559934 | METHOD FOR THE PRODUCTION OF AN ANTIBODY | Final Rejection | Hoffmann-La Roche Inc. |
| 16651911 | FORMULATIONS | Final Rejection | Intellia Therapeutics, Inc. |
| 18282061 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | Final Rejection | UCL BUSINESS LTD |
| 18690014 | GENETIC RESISTANCE TO VIRAL DISEASE IN SALMONID FISH | Non-Final OA | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16609733 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Final Rejection | Juno Therapeutics, Inc. |
| 18628222 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18915595 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | Non-Final OA | Purdue Research Foundation |
| 17768002 | GENETICALLY MODIFIED HUMAN STEM CELL EXPRESSING A MUTANT HUMAN CYTOCHROME P450 2B6 PROTEIN AND ITS USE THEREOF IN THE TREATMENT OF CANCER | Final Rejection | SORBONNE UNIVERSITE |
| 18973640 | COMPOSITIONS FOR MODULATING AN XBP1 PATHWAY IN A KERATINOCYTE AND METHODS OF USE | Non-Final OA | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | Non-Final OA | Children's Healthcare of Atlanta, Inc. |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18851407 | METHOD FOR THAWING BIOLOGICALLY-DERIVED FROZEN MATERIAL BY VERY HIGH FREQUENCY ELECTROMAGNETIC WAVE IRRADIATION, CRYOPRECIPITATE PRODUCING METHOD, AND THAWING DEVICE | Non-Final OA | Hidenobu HARADA |
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Non-Final OA | ENGENE, INC. |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | Non-Final OA | City of Hope |
| 18644724 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18624753 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | Voyager Therapeutics, Inc. |
| 18029112 | Use of an intervertebral disc fibrosis-inducing substance in preparation of medication | Non-Final OA | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
| 18411732 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | Final Rejection | C3S2 GMBH |
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | Final Rejection | AUTOLUS LIMITED |
| 18565253 | CELL CULTURE SUPPLEMENT FOR PRODUCING STEM CELLS, AND METHOD FOR PRODUCING STEM CELLS | Final Rejection | OPTICELL, INC |
| 18564318 | SCAFFOLD FOR CELL CULTURE | Final Rejection | SEA WITH, INC |
| 18238074 | POLYMERIC MICELLE COMPOSITIONS | Final Rejection | UVic Industry Partnerships Inc.- Univ. of Victoria |
| 18017636 | 5' S/MAR APPLICATIONS | Non-Final OA | Deutsches Krebsforschungszentrum |
| 18143506 | GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT | Non-Final OA | Research Foundation to Cure AIDS, Inc. |
| 18050089 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | Final Rejection | JPV01 LTD. |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | Final Rejection | Exuma Biotech Corp. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.4% of resolved applications examined by Michael D Burkhart were allowed (846 resolved cases), compared with 34.8% across Art Unit 1633 over the last five years.
This examiner's interview lift is +11.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Michael D Burkhart took 1,217 days on average from filing to allowance.
Michael D Burkhart examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
